# Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

> **NCT02038816** · PHASE2 · TERMINATED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 1 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Deferasirox + Azacitidine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT02038816
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2016-09-29
- **Final completion:** 2016-09-29
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** accrual too slow, insufficient patients
- **Last updated:** 2018-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038816, "Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02038816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*